DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
22.97B
Market cap22.97B
Price-Earnings ratio
27.55
Price-Earnings ratio27.55
Dividend yield
Dividend yield
Average volume
4.56M
Average volume4.56M
High today
$64.98
High today$64.98
Low today
$55.00
Low today$55.00
Open price
$58.03
Open price$58.03
Volume
5.34M
Volume5.34M
52 Week high
$89.98
52 Week high$89.98
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

DexCom(DXCM) stock is priced at $59.15, giving the company a market capitalization of 22.97B. It carries a P/E multiple of 27.55.

On 2026-05-01, DexCom(DXCM) stock moved within a range of $55.00 to $64.98. With shares now at $59.15, the stock is trading +7.5% above its intraday low and -9.0% below the session's peak.

Trading volume for DexCom(DXCM) stock has reached 5.34M, versus its average volume of 4.56M.

The stock's 52-week range extends from a low of $54.11 to a high of $89.98.

The stock's 52-week range extends from a low of $54.11 to a high of $89.98.

DXCM News

TipRanks 7h
Buy Rating Reaffirmed on Dexcom as Margin Strength and Global Patient Growth Offset U.S. CGM Concerns; Price Target Reset to $75

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Dexcom. The associated price target was lowered to $75.00. Unlock hedge fund-level data a...

Nasdaq 10h
DexCom Q1 2026 Earnings Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

DexCom Q1 2026 Earnings Transcript
TipRanks 12h
DexCom affirms FY26 revenue $5.16B-$5.25B, consensus $5.23B

Dexcom (DXCM) is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin: Non-GAAP Gross Profit Margin of approximately 63-64...

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
12.9%
Sell
3.2%

More DXCM News

Simply Wall St 1d
Is DexCom’s G7 Sensor Upgrade Quietly Redefining Its Core Recurring-Revenue Story?

DexCom, Inc. recently drew increased attention ahead of its past-Thursday earnings release, as analysts raised revenue estimates and focused on its continuous g...

Is DexCom’s G7 Sensor Upgrade Quietly Redefining Its Core Recurring-Revenue Story?
Simply Wall St 3d
Is DexCom Now Attractive After Recent Share Price Weakness?

Wondering if DexCom at around US$61.41 is a bargain or a value trap? This breakdown will help you weigh what the current price really offers. The stock has rec...

Is DexCom Now Attractive After Recent Share Price Weakness?

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.